[1] PIEPOLI MF, HOES AW, AGEWALL S, et al.2016 European Guidelines on cardiovascular disease prevention in clinical practice[J].Rev Esp Cardiol (Engl Ed), 2016, 69(10):939.
[2] 陈伟伟, 高润霖, 刘力生, 等.《中国心血管病报告2016》概要[J].中国循环杂志, 2017, 32(6):521. doi: 10.3969/j.issn.1000-3614.2017.06.001
[3] NISHIMURA RA, OTTO CM, BONOW RO, et al.2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].J Am Coll Cardiol, 2017, 70(2):252. doi: 10.1016/j.jacc.2017.03.011
[4] KHERA AV, KATHIRESAN S.Genetics of coronary artery disease:discovery, biology and clinical translation[J].Nat Rev Genet, 2017, 18(6):331. doi: 10.1038/nrg.2016.160
[5] SHULDINER AR, O'CONNELL JR, BLIDEN KP, et al.Association of cytochrome P4502C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA, 2009, 302(8):849. doi: 10.1001/jama.2009.1232
[6] LI C, ZHANG L, WANG H, et al.Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention-A multicenter study[J].Int J Cardiol, 2017, 240:360. doi: 10.1016/j.ijcard.2017.03.015
[7] ROFFI M, PATRONO C, COLLET J P, et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J].Eur Heart J, 2016, 37(3):267. doi: 10.1093/eurheartj/ehv320
[8] ROFFI M, PATRONO C, COLLET J P, et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J].Kardiol Pol, 2015, 73(12):1207. doi: 10.5603/KP.2015.0243
[9] 沈卫峰.《急性ST段抬高型心肌梗死诊断和治疗指南》要点介绍[J].心脑血管病防治, 2015, 15(3):173. doi: 10.3969/j.issn.1009-816X.2015.03.001
[10] LEVINE GN, BATES ER, BLANKENSHIP JC, et al.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J].J Am Coll Cardiol, 2011, 58(24):e44. doi: 10.1016/j.jacc.2011.08.007
[11] O'GARA PT, KUSHNER FG, ASCHEIM DD, et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol, 2013, 61(4):e78. doi: 10.1016/j.jacc.2012.11.019
[12] MOZAFFARIAN D, BENJAMIN EJ, GO AS, et al.Heart disease and stroke statistics-2016 update:a report from the american heart association[J].Circulation, 2016, 133(4):e38.
[13] 李妙男, 王洪巨, 汤阳, 等.血浆细胞色素P4502C19基因多态性与皖北汉族急性冠脉综合征病人氯吡格雷抵抗及冠脉介入术后近期预后的关系[J].临床心血管病杂志, 2016, 32(3):272.
[14] WEI YQ, WANG DG, YANG H, et al.Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome[J].PLoS One, 2015, 10(7):e132561.
[15] LIU J, NIE XY, ZHANG Y, et al.CYP2C19*2 and other allelic variants affecting platelet response to clopidogrel tested by thrombelastography in patients with acute coronary syndrome[J].Chin Med J (Engl), 2015, 128(16):2183. doi: 10.4103/0366-6999.162515
[16] WANG X, LAI Y, LUO Y, et al.Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year:A cohort study from Han Chinese[J].J Res Med Sci, 2016, 21(1):111. doi: 10.4103/1735-1995.193502
[17] SUN Q, JIA X, GAO J, et al.Association of serum homocysteine levels with the severity and calcification of coronary atherosclerotic plaques detected by coronary CT angiography[J].Int Angiol, 2014, 33(4):316.
[18] HASSAN A, DOHI T, MIYAUCHI K, et al.Prognostic impact of homocysteine levels and homocysteine thiolactonase activity on long-term clinical outcomes in patients undergoing percutaneous coronary intervention[J].J Cardiol, 2017, 69(6):830. doi: 10.1016/j.jjcc.2016.08.013
[19] CHAN MY, NEELY ML, ROE MT, et al.Temporal biomarker profiling reveals longitudinal changes in risk of death or myocardial infarction in non-ST-segment elevation acute coronary syndrome[J].Clin Chem, 2017, 63(7):1214. doi: 10.1373/clinchem.2016.265272